Intervention Protocol

Optimal timing for discontinuation of Pneumocystis jiroveci pneumonia prophylaxis in adult patients on highly active antiretroviral therapy (HAART) for HIV infection

  1. Elizabeth Mbabazi1,*,
  2. Olalekan A Uthman2,
  3. Taryn Young3

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 18 JAN 2012

Assessed as up-to-date: 13 APR 2011

DOI: 10.1002/14651858.CD009556


How to Cite

Mbabazi E, Uthman OA, Young T. Optimal timing for discontinuation of Pneumocystis jiroveci pneumonia prophylaxis in adult patients on highly active antiretroviral therapy (HAART) for HIV infection (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD009556. DOI: 10.1002/14651858.CD009556.

Author Information

  1. 1

    University of Stellenbosch, Division of Community Health, Cape Town, Western Cape, South Africa

  2. 2

    Keele University, Primary Care Sciences, Keele, Staffordshire, UK

  3. 3

    Stellenbosch University, Centre for Evidence-based Health Care, Faculty of Health Sciences, Tygerberg, South Africa

*Elizabeth Mbabazi, Division of Community Health, University of Stellenbosch, Tygerberg Campus, Cape Town, Western Cape, 7505, South Africa. komugishaliz@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 18 JAN 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the impact of discontinuation of Pneumocystis jiroveci prophylaxis on the morbidity and mortality due to Pneumocystis jiroveci pneumonia in HIV patients who show a stable rise in CD4 counts to >200cells/mm3for three or more months following initiation of HAART.